Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Actavis Executive VP-U.S. Commercial And Administration Doug Boothe: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

This article was originally published in The Pink Sheet Daily

Executive Summary

Boothe talks with “The Pink Sheet” DAILY about Actavis’ global and U.S. strategies as the top five generics company looks to keep growing.

You may also be interested in...



Actavis Gets New CEO As Growth Strategy Shifts To Targeted Buys

As Actavis revamps its manufacturing strategy in New Jersey, the firm will have new leadership at its headquarters in Hafnarfjordur, Iceland. Robert Wessman stepped down as CEO of Actavis Group Aug. 5, after serving in the position with Actavis Group for nearly 10 years. Wessman, who will remain on the Board of Directors, wants to focus on his company, Salt Investments.

Actavis Executive VP-U.S. Commercial And Administration Doug Boothe: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)

Boothe talks with “The Pink Sheet” DAILY about follow-on biologics and other issues facing the generics industry, as well as how the top-five generics company is positioning itself to thrive in an evolving global environment.

Actavis Executive VP-U.S. Commercial And Administration Doug Boothe: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)

Boothe talks with “The Pink Sheet” DAILY about follow-on biologics and other issues facing the generics industry, as well as how the top-five generics company is positioning itself to thrive in an evolving global environment.

Related Content

Topics

UsernamePublicRestriction

Register

GB140150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel